Global Peptide Therapeutics Market Size, Forecast: By Type: Branded Peptide, Generics Peptide; By Applications: Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, Others; By Route of Administration; By Type of Manufactures; By Distribution Channels; Regional Analysis; Supplier Landscape; 2024-2032

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Peptide Therapeutics Market Overview 
    3.1    Global Peptide Therapeutics Market Historical Value (2017-2023) 
    3.2    Global Peptide Therapeutics Market Forecast Value (2024-2032)
4    Global Peptide Therapeutics Market Landscape
    4.1    Global Peptide Therapeutics Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Peptide Therapeutics Product Landscape
        4.2.1    Analysis by Type
        4.2.2    Analysis by Distribution Channel
        4.2.3    Analysis by Applications
5    Global Peptide Therapeutics Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Peptide Therapeutics Market Segmentation 
    6.1    Global Peptide Therapeutics Market by Type
        6.1.1    Market Overview
        6.1.2    Branded Peptide
        6.1.3    Generics Peptide
    6.2    Global Peptide Therapeutics Market by Applications
        6.2.1    Market Overview
        6.2.2    Cancer, Cardiovascular Disease
        6.2.3    Metabolic Disease
        6.2.4    Respiratory Disease
        6.2.5    Infectious Disease
        6.2.6    Others
    6.3    Global Peptide Therapeutics Market by Route of Administration
        6.3.1    Market Overview
        6.3.2    Oral
            6.3.2.1    Tablets 
            6.3.2.2    Capsules
        6.3.3    Parenteral
            6.3.3.1    Intravascular
            6.3.3.2    intramuscular
    6.4    Global Peptide Therapeutics Market by Type of Manufactures
        6.4.1    Market Overview
        6.4.2    In House
        6.4.3    Outsourced
    6.5    Global Peptide Therapeutics Market by Distribution Channels
        6.5.1    Market Overview
        6.5.2    Hospitals Pharmacies
        6.5.3    Retail Pharmacies
        6.5.4    Online Pharmacies
        6.5.5    Others
    6.6    Global Peptide Therapeutics Market by Region
        6.6.1    Market Overview
        6.6.2    North America 
        6.6.3    Europe
        6.6.4    Asia Pacific
        6.6.5    Latin America
        6.6.6    Middle East and Africa
7    North America Peptide Therapeutics Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Peptide Therapeutics Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Peptide Therapeutics Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Peptide Therapeutics Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Peptide Therapeutics Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Clinical Trials Analysis 
    14.1     Analysis by Trial Registration Year 
    14.2    Analysis by Trial Status 
    14.3    Analysis by Trial Phase 
    14.4    Analysis by Therapeutic Area 
    14.5    Analysis by Geography 
15    Funding Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Supplier Landscape
    18.1    F. Hoffmann-La Roche Ltd.
        18.1.1    Financial Analysis
        18.1.2    Product Portfolio
        18.1.3    Demographic Reach and Achievements
        18.1.4    Mergers and Acquisitions
        18.1.5    Certifications
    18.2    GlaxoSmithKline plc.
        18.2.1    Financial Analysis
        18.2.2    Product Portfolio
        18.2.3    Demographic Reach and Achievements
        18.2.4    Mergers and Acquisitions
        18.2.5    Certifications
    18.3    Novartis AG
        18.3.1    Financial Analysis
        18.3.2    Product Portfolio
        18.3.3    Demographic Reach and Achievements
        18.3.4    Mergers and Acquisitions
        18.3.5    Certifications
    18.4    Pfizer, Inc.
        18.4.1    Financial Analysis
        18.4.2    Product Portfolio
        18.4.3    Demographic Reach and Achievements
        18.4.4    Mergers and Acquisitions
        18.4.5    Certifications
    18.5    Sanofi
        18.5.1    Financial Analysis
        18.5.2    Product Portfolio
        18.5.3    Demographic Reach and Achievements
        18.5.4    Mergers and Acquisitions
        18.5.5    Certifications
    18.6    Takeda Pharmaceutical Company Limited
        18.6.1    Financial Analysis
        18.6.2    Product Portfolio
        18.6.3    Demographic Reach and Achievements
        18.6.4    Mergers and Acquisitions
        18.6.5    Certifications
    18.7    Teva Pharmaceutical Industries Ltd
        18.7.1    Financial Analysis
        18.7.2    Product Portfolio
        18.7.3    Demographic Reach and Achievements
        18.7.4    Mergers and Acquisitions
        18.7.5    Certifications
    18.8    Ipsen Pharma
        18.8.1    Financial Analysis
        18.8.2    Product Portfolio
        18.8.3    Demographic Reach and Achievements
        18.8.4    Mergers and Acquisitions
        18.8.5    Certifications
    18.9     AstraZeneca
        18.9.1    Financial Analysis
        18.9.2    Product Portfolio
        18.9.3    Demographic Reach and Achievements
        18.9.4    Mergers and Acquisitions
        18.9.5    Certifications
    18.10    Lonza
        18.10.1    Financial Analysis
        18.10.2    Product Portfolio
        18.10.3    Demographic Reach and Achievements
        18.10.4    Mergers and Acquisitions
        18.10.5    Certifications
    18.11    Merck Sharp & Dohme Corp.
        18.11.1    Financial Analysis
        18.11.2    Product Portfolio
        18.11.3    Demographic Reach and Achievements
        18.11.4    Mergers and Acquisitions
        18.11.5    Certifications
    18.12    Novo Nordisk A/S
        18.12.1    Financial Analysis
        18.12.2    Product Portfolio
        18.12.3    Demographic Reach and Achievements
        18.12.4    Mergers and Acquisitions
        18.12.5    Certifications
    18.13    PolyPeptide Group
        18.13.1    Financial Analysis
        18.13.2    Product Portfolio
        18.13.3    Demographic Reach and Achievements
        18.13.4    Mergers and Acquisitions
        18.13.5    Certifications
    18.14    CordenPharma International
        18.14.1    Financial Analysis
        18.14.2    Product Portfolio
        18.14.3    Demographic Reach and Achievements
        18.14.4    Mergers and Acquisitions
        18.14.5    Certifications
19    Global Peptide Therapeutics Distribution Model (Additional Insight)
    19.1    Overview 
    19.2    Potential Distributors 
    19.3    Key Parameters for Distribution Partner Assessment 
20    Key Opinion Leaders (KOL) Insights (Additional Insight)
21    Company Competitiveness Analysis (Additional Insight)
    21.1    Very Small Companies
    21.2    Small Companies
    21.3    Mid-Sized Companies
    21.4    Large Companies
    21.5    Very Large Companies
22    Payment Methods (Additional Insight)
    22.1    Government Funded
    22.2    Private Insurance
    22.3    Out-of-Pocket

*Additional insights provided are customisable as per client requirements.